

SALSA® MLPA® is the method of choice for the detection of CNVs in genes associated with hereditary cancer. MRC Holland offers over 40 MLPA assays specifically designed to detect CNVs and selected SNVs in hundreds of oncogenes.


digitalMLPA™ combines the robustness and simplicity of MLPA with the high throughput of NGS platforms. Our digitalMLPA NXtec™ Hereditary Cancer Panels are targeted assays to examine CNVs and selected SNVs in cancer-predisposing genes.

Both technologies share key features that make them well-suited for germline analysis:

- ▶ Unparalleled CNV sensitivity even in complex genetic regions, such as *PMS2* and *PTEN*.
- ▶ Wide CNV detection range – from whole chromosomes to single exons.
- ▶ Free software, simple analysis and clear-cut results.

## MLPA

- ✓ Multiplex PCR-based method for CNV, methylation and targeted SNV detection
- ✓ Needed: thermocycler and capillary electrophoresis device
- ✓ 40-60 targets per reaction
- ✓ 50 ng of DNA input per sample




### Top-Selling Applications

|                                      |                                                                               |
|--------------------------------------|-------------------------------------------------------------------------------|
| Hereditary Breast and Ovarian Cancer | P002 BRCA1<br>P045 BRCA2/CHEK2<br>P041 ATM-1 / P042 ATM-2                     |
| Lynch Syndrome                       | P003 MLH1/MSH2<br>P008 PMS2<br>P072 MSH6-MUTYH<br>ME011 Mismatch Repair Genes |
| Neurofibromatosis                    | P081 NF1 mix 1 / P082 NF1 mix 2<br>P122 NF1-area<br>P044 NF2                  |

## digitalMLPA

- ✓ NGS-based MLPA for CNV and targeted SNV detection
- ✓ Needed: thermocycler and NGS platform
- ✓ Up to 1600 targets per reaction
- ✓ 20 ng of DNA input per sample
- ✓ Combine digitalMLPA with other libraries to maximise sequencing capacity



### NXtec D002 Hereditary Cancer Panel 2

Broad panel targeting a wide range of genes associated with hereditary predisposition to various types of cancer.

|        |        |            |         |
|--------|--------|------------|---------|
| APC    | EPCAM  | NTHL1      | SDHAF2  |
| ATM    | FH     | PALB2      | SDHB    |
| BAP1   | FLCN   | PHOX2B     | SDHC    |
| BARD1  | HOXB13 | PMS2       | SDHD    |
| BMPRIA | MAX    | POLD1      | SMAD4   |
| BRCA1  | MEN1   | POLE       | SMARCB1 |
| BRCA2  | MET    | PTCH1      | STK11   |
| BRIP1  | MLH1   | PTEN       | SUFU    |
| CDH1   | MSH2   | RAD51C     | TMEM127 |
| CDK4   | MSH6   | RAD51D     | TP53    |
| CDKN2A | MUTYH  | RB1        | TSC1    |
| CEBPA  | NBN    | RUNX1      | TSC2    |
| CHEK2  | NF1    | SCG5/GREM1 | VHL     |
| DICER1 | NF2    | SDHA       | WT1     |

## Broad Hereditary Cancer Panels

| digitalMLPA assay                                                                                              | Target genes/regions                                                                                                                                                                                               |
|----------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>NXtec D001 Hereditary Cancer Panel 1</b><br>Focused, cost-effective panel, targeting 8 common cancer types. | <i>APC, ATM, BAP1, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, CHEK2, EPCAM, MITF (p.E318K), MLH1, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, POLE, PTEN, RAD51C, RAD51D, SCG5/GREM1, SMAD4, STK11, TP53</i> |
| <b>NXtec D002 Hereditary Cancer Panel 2</b><br>Broad, expanded panel targeting a wide range of cancer types.   | Includes all D001 targets and additional, D002-exclusive targets. See front of flyer for complete list of targeted genes/regions.                                                                                  |

## Breast, Endometrial and Ovarian Cancer

| SALSA® MLPA® Probemix                 | Target genes/regions                                                                                               |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------|
| <b>ME011</b> Mismatch Repair Genes*   | <i>MLH1</i> methylation, <i>BRAF</i> p.V600E point mutation and associated Lynch syndrome genome changes profiling |
| <b>P002</b> BRCA1†                    | <i>BRCA1</i>                                                                                                       |
| <b>P003</b> MLH1/MSH2†                | <i>MLH1, MSH2</i>                                                                                                  |
| <b>P008</b> PMS2                      | <i>PMS2</i>                                                                                                        |
| <b>P041</b> ATM-1 / <b>P042</b> ATM-2 | <i>ATM</i>                                                                                                         |
| <b>P045</b> BRCA2/CHEK2†              | <i>BRCA2, CHEK2</i>                                                                                                |
| <b>P057</b> FANCD2-PALB2              | <i>FANCD2, PALB2</i>                                                                                               |
| <b>P072</b> MSH6-MUTYH                | <i>MSH6, MUTYH, MSH2, EPCAM</i>                                                                                    |
| <b>P083</b> CDH1                      | <i>CDH1</i>                                                                                                        |
| <b>P090</b> BRCA2†                    | <i>BRCA2</i>                                                                                                       |
| <b>P190</b> CHEK2                     | <i>CHEK2, ATM, TP53</i>                                                                                            |
| <b>P225</b> PTEN                      | <i>PTEN, PTENP1</i>                                                                                                |
| <b>P239</b> BRCA1 region              | <i>BRCA1</i> region                                                                                                |
| <b>P240</b> BRIP1/CHEK1               | <i>BRIP1, CHEK1</i>                                                                                                |
| <b>P260</b> PALB2-RAD50-RAD51C-RAD51D | <i>PALB2, RAD50, RAD51C, RAD51D</i>                                                                                |
| <b>P489</b> BARD1                     | <i>BARD1</i>                                                                                                       |
| <b>P494</b> NBN                       | <i>NBN</i>                                                                                                         |
| <b>P499</b> EPCAM                     | <i>EPCAM, MSH2</i> <b>NEW*</b>                                                                                     |

## Skin Cancer

| SALSA® MLPA® Probemix                 | Target genes/regions                                                              |
|---------------------------------------|-----------------------------------------------------------------------------------|
| <b>ME024</b> 9p21 CDKN2A/2B region*   | <i>CDKN2A/2B, MTAP, MIR31, PAX5</i> and methylation profiling of <i>CDKN2A/2B</i> |
| <b>P041</b> ATM-1 / <b>P042</b> ATM-2 | <i>ATM</i>                                                                        |
| <b>P417</b> BAP1                      | <i>BAP1</i>                                                                       |
| <b>P419</b> CDKN2A/2B-CDK4            | <i>CDKN2A/2B, CDK4, MTAP, MITF (p.E318K)</i>                                      |
| <b>P472</b> SUFU                      | <i>SUFU</i>                                                                       |

## Pancreatic Cancer

| SALSA® MLPA® Probemix               | Target genes/regions                                                              |
|-------------------------------------|-----------------------------------------------------------------------------------|
| <b>ME024</b> 9p21 CDKN2A/2B region* | <i>CDKN2A/2B, MTAP, MIR31, PAX5</i> and methylation profiling of <i>CDKN2A/2B</i> |
| <b>P003</b> MLH1/MSH2†              | <i>MLH1, MSH2</i>                                                                 |
| <b>P045</b> BRCA2/CHEK2†            | <i>BRCA2, CHEK2</i>                                                               |
| <b>P090</b> BRCA2†                  | <i>BRCA2</i>                                                                      |
| <b>P419</b> CDKN2A/2B-CDK4          | <i>CDKN2A/2B, CDK4, MITF (p.E318K)</i>                                            |

## Hematological Malignancies

| SALSA® MLPA® Probemix                              | Target genes/regions                                                   |
|----------------------------------------------------|------------------------------------------------------------------------|
| <b>P031</b> FANCA mix 1<br><b>P032</b> FANCA mix 2 | <i>FANCA</i>                                                           |
| <b>P057</b> FANCD2-PALB2                           | <i>FANCD2, PALB2</i>                                                   |
| <b>P113</b> FANCB                                  | <i>FANCB</i>                                                           |
| <b>P212</b> DBA                                    | <i>RPL11, RPL35A, RPS17, RPS19, RPS26, RPL5</i>                        |
| <b>P327</b> iAMP21-ERG                             | <i>iAMP21, RUNX1, ERG</i>                                              |
| <b>P437</b> Familial MDS-AML                       | <i>GATA2 (+p.R398W, p.T354M), TERC, TERT (+p.A1062T), CEBPA, RUNX1</i> |

† A separate MLPA confirmation probemix is available, containing independent probes targeting the same exons/genes as the primary probemix.  
\* This probemix also includes probes that determine the methylation status of a target.  
\* Release expected 2026-Q4.

## Broad Cancer-Predisposing Syndromes

| SALSA® MLPA® Probemix                         | Target genes/regions                                                                                               |
|-----------------------------------------------|--------------------------------------------------------------------------------------------------------------------|
| <b>ME011</b> Mismatch Repair Genes*           | <i>MLH1</i> methylation, <i>BRAF</i> p.V600E point mutation and associated Lynch syndrome genome changes profiling |
| <b>P016</b> VHL                               | <i>VHL</i>                                                                                                         |
| <b>P017</b> MEN1                              | <i>MEN1</i>                                                                                                        |
| <b>P044</b> NF2                               | <i>NF2</i>                                                                                                         |
| <b>P046</b> TSC2†                             | <i>TSC2</i>                                                                                                        |
| <b>P056</b> TP53                              | <i>TP53, CHEK2 (+c.del1100C)</i>                                                                                   |
| <b>P057</b> FANCD2-PALB2                      | <i>FANCD2, PALB2</i>                                                                                               |
| <b>P067</b> PTCH1                             | <i>PTCH1</i>                                                                                                       |
| <b>P081</b> NF1 mix 1 / <b>P082</b> NF1 mix 2 | <i>NF1</i>                                                                                                         |
| <b>P101</b> STK11                             | <i>STK11</i>                                                                                                       |
| <b>P118</b> WT1                               | <i>WT1, AMER1</i>                                                                                                  |
| <b>P122</b> NF1-area                          | <i>NF1-area</i>                                                                                                    |
| <b>P124</b> TSC1                              | <i>TSC1</i>                                                                                                        |
| <b>P215</b> EXT                               | <i>EXT1, EXT2</i>                                                                                                  |
| <b>P225</b> PTEN                              | <i>PTEN, PTENP1</i>                                                                                                |
| <b>P226</b> SDH                               | <i>SDHB, SDHC, SDHD, SDHAF1, SDHAF2</i>                                                                            |
| <b>P244</b> AIP-MEN1-CDKN1B                   | <i>AIP, MEN1, CDKN1B</i>                                                                                           |
| <b>P258</b> SMARCB1                           | <i>SMARCB1</i>                                                                                                     |
| <b>P308</b> MET                               | <i>MET, PTEN, LRRK2</i>                                                                                            |
| <b>P417</b> BAP1                              | <i>BAP1</i>                                                                                                        |
| <b>P429</b> SDHA-MAX-TMEM127                  | <i>SDHA, MAX, TMEM127</i>                                                                                          |
| <b>P437</b> Familial MDS-AML                  | <i>GATA2 (+p.R398W, p.T354M), TERC, TERT (+p.A1062T), CEBPA, RUNX1</i>                                             |
| <b>P455</b> LZTR1                             | <i>LZTR1</i>                                                                                                       |
| <b>P466</b> CDC73                             | <i>CDC73</i>                                                                                                       |
| <b>P478</b> SMARCE1                           | <i>SMARCE1</i>                                                                                                     |
| <b>P481</b> PRKAR1A-ARMC5                     | <i>PRKAR1A, ARMC5</i>                                                                                              |
| <b>P482</b> DICER1                            | <i>DICER1</i>                                                                                                      |
| <b>P499</b> EPCAM                             | <i>EPCAM, MSH2</i> <b>NEW*</b>                                                                                     |

## Gastrointestinal Cancer

| SALSA® MLPA® Probemix               | Target genes/regions                                                                                               |
|-------------------------------------|--------------------------------------------------------------------------------------------------------------------|
| <b>ME011</b> Mismatch Repair Genes* | <i>MLH1</i> methylation, <i>BRAF</i> p.V600E point mutation and associated Lynch syndrome genome changes profiling |
| <b>P003</b> MLH1/MSH2†              | <i>MLH1, MSH2</i>                                                                                                  |
| <b>P008</b> PMS2                    | <i>PMS2</i>                                                                                                        |
| <b>P043</b> APC                     | <i>APC</i>                                                                                                         |
| <b>P072</b> MSH6-MUTYH              | <i>MSH6, MUTYH, MSH2, EPCAM</i>                                                                                    |
| <b>P083</b> CDH1                    | <i>CDH1</i>                                                                                                        |
| <b>P158</b> JPS                     | <i>BMPR1A, SMAD4, PTEN</i>                                                                                         |
| <b>P190</b> CHEK2                   | <i>CHEK2, ATM, TP53</i>                                                                                            |
| <b>P378</b> MUTYH                   | <i>MUTYH, SCG5/GREM1</i>                                                                                           |
| <b>P492</b> POLD1-POLE              | <i>POLD1, POLE</i>                                                                                                 |
| <b>P499</b> EPCAM                   | <i>EPCAM, MSH2</i> <b>NEW*</b>                                                                                     |

## Other Cancers

| SALSA® MLPA® Probemix  | Target genes/regions                                   |
|------------------------|--------------------------------------------------------|
| <b>P003</b> MLH1/MSH2† | <i>MLH1, MSH2</i>                                      |
| <b>P047</b> RB1*       | <i>RB1+</i> flanking, <i>RB1</i> methylation profiling |
| <b>P067</b> PTCH1      | <i>PTCH1</i>                                           |
| <b>P256</b> FLCN       | <i>FLCN</i>                                            |
| <b>P472</b> SUFU       | <i>SUFU</i>                                            |